LENZ Therapeutics, Inc.
LENZ
$4.73
$0.132.83%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 188.58% | 19.71% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 188.58% | 19.71% | |||
| Cost of Revenue | -73.98% | 157.42% | |||
| Gross Profit | 531.03% | -29.49% | |||
| SG&A Expenses | -12.42% | 13.44% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -13.85% | 14.94% | |||
| Operating Income | 22.57% | -14.75% | |||
| Income Before Tax | 23.07% | -15.58% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 23.07% | -15.58% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 23.07% | -15.58% | |||
| EBIT | 22.57% | -14.75% | |||
| EBITDA | 22.63% | -14.78% | |||
| EPS Basic | 23.12% | -14.54% | |||
| Normalized Basic EPS | 23.12% | -14.54% | |||
| EPS Diluted | 23.12% | -14.54% | |||
| Normalized Diluted EPS | 23.12% | -14.54% | |||
| Average Basic Shares Outstanding | 0.07% | 0.91% | |||
| Average Diluted Shares Outstanding | 0.07% | 0.91% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||